Conjugation Dependent Interaction of Folic Acid with Folate Binding Protein

Rachel L. Merzel, Carolina Frey, Junjie Chen, Rachel Garn, Mallory Van Dongen, Casey A. Dougherty, Ananda Kumar Kandaluru, Philip S. Low, E. Neil G. Marsh, Mark M. Banaszak Holl

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Serum proteins play a critical role in the transport, uptake, and efficacy of targeted drug therapies, and here we investigate the interactions between folic acid-polymer conjugates and serum folate binding protein (FBP), the soluble form of the cellular membrane-bound folate receptor. We demonstrate that both choice of polymer and method of ligand conjugation affect the interactions between folic acid-polymer conjugates and serum FBP, resulting in changes in the folic acid-induced protein aggregation process. We have previously demonstrated that individual FBP molecules self-aggregate into nanoparticles at physiological concentrations. When poly(amidoamine) dendrimer-folic acid conjugates bound to FBP, the distribution of nanoparticles was preserved. However, the dendritic conjugates produced larger nanoparticles than those formed in the presence of physiologically normal human levels of folic acid, and the conjugation method affected particle size distribution. In contrast, poly(ethylene glycol)-folic acid conjugates demonstrated substantially reduced binding to FBP, did not cause folic acid-induced aggregation, and fully disrupted FBP self-aggregation. On the basis of these results, we discuss the potential implications for biodistribution, trafficking, and therapeutic efficacy of targeted nanoscale therapeutics, especially considering the widespread clinical use of poly(ethylene glycol) conjugates. We highlight the importance of considering specific serum protein interactions in the rational design of similar nanocarrier systems. Our results suggest that prebinding therapeutic nanocarriers to serum FBP may allow folate-specific metabolic pathways to be exploited for delivery while also affording benefits of utilizing an endogenous protein as a vector.

Original languageEnglish
Pages (from-to)2350-2360
Number of pages11
JournalBioconjugate Chemistry
Volume28
Issue number9
DOIs
Publication statusPublished - 20 Sep 2017
Externally publishedYes

Cite this

Merzel, Rachel L. ; Frey, Carolina ; Chen, Junjie ; Garn, Rachel ; Van Dongen, Mallory ; Dougherty, Casey A. ; Kandaluru, Ananda Kumar ; Low, Philip S. ; Marsh, E. Neil G. ; Banaszak Holl, Mark M. / Conjugation Dependent Interaction of Folic Acid with Folate Binding Protein. In: Bioconjugate Chemistry. 2017 ; Vol. 28, No. 9. pp. 2350-2360.
@article{5931933acc05467ea4f3feeb08c39586,
title = "Conjugation Dependent Interaction of Folic Acid with Folate Binding Protein",
abstract = "Serum proteins play a critical role in the transport, uptake, and efficacy of targeted drug therapies, and here we investigate the interactions between folic acid-polymer conjugates and serum folate binding protein (FBP), the soluble form of the cellular membrane-bound folate receptor. We demonstrate that both choice of polymer and method of ligand conjugation affect the interactions between folic acid-polymer conjugates and serum FBP, resulting in changes in the folic acid-induced protein aggregation process. We have previously demonstrated that individual FBP molecules self-aggregate into nanoparticles at physiological concentrations. When poly(amidoamine) dendrimer-folic acid conjugates bound to FBP, the distribution of nanoparticles was preserved. However, the dendritic conjugates produced larger nanoparticles than those formed in the presence of physiologically normal human levels of folic acid, and the conjugation method affected particle size distribution. In contrast, poly(ethylene glycol)-folic acid conjugates demonstrated substantially reduced binding to FBP, did not cause folic acid-induced aggregation, and fully disrupted FBP self-aggregation. On the basis of these results, we discuss the potential implications for biodistribution, trafficking, and therapeutic efficacy of targeted nanoscale therapeutics, especially considering the widespread clinical use of poly(ethylene glycol) conjugates. We highlight the importance of considering specific serum protein interactions in the rational design of similar nanocarrier systems. Our results suggest that prebinding therapeutic nanocarriers to serum FBP may allow folate-specific metabolic pathways to be exploited for delivery while also affording benefits of utilizing an endogenous protein as a vector.",
author = "Merzel, {Rachel L.} and Carolina Frey and Junjie Chen and Rachel Garn and {Van Dongen}, Mallory and Dougherty, {Casey A.} and Kandaluru, {Ananda Kumar} and Low, {Philip S.} and Marsh, {E. Neil G.} and {Banaszak Holl}, {Mark M.}",
year = "2017",
month = "9",
day = "20",
doi = "10.1021/acs.bioconjchem.7b00373",
language = "English",
volume = "28",
pages = "2350--2360",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "9",

}

Merzel, RL, Frey, C, Chen, J, Garn, R, Van Dongen, M, Dougherty, CA, Kandaluru, AK, Low, PS, Marsh, ENG & Banaszak Holl, MM 2017, 'Conjugation Dependent Interaction of Folic Acid with Folate Binding Protein', Bioconjugate Chemistry, vol. 28, no. 9, pp. 2350-2360. https://doi.org/10.1021/acs.bioconjchem.7b00373

Conjugation Dependent Interaction of Folic Acid with Folate Binding Protein. / Merzel, Rachel L.; Frey, Carolina; Chen, Junjie; Garn, Rachel; Van Dongen, Mallory; Dougherty, Casey A.; Kandaluru, Ananda Kumar; Low, Philip S.; Marsh, E. Neil G.; Banaszak Holl, Mark M.

In: Bioconjugate Chemistry, Vol. 28, No. 9, 20.09.2017, p. 2350-2360.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Conjugation Dependent Interaction of Folic Acid with Folate Binding Protein

AU - Merzel, Rachel L.

AU - Frey, Carolina

AU - Chen, Junjie

AU - Garn, Rachel

AU - Van Dongen, Mallory

AU - Dougherty, Casey A.

AU - Kandaluru, Ananda Kumar

AU - Low, Philip S.

AU - Marsh, E. Neil G.

AU - Banaszak Holl, Mark M.

PY - 2017/9/20

Y1 - 2017/9/20

N2 - Serum proteins play a critical role in the transport, uptake, and efficacy of targeted drug therapies, and here we investigate the interactions between folic acid-polymer conjugates and serum folate binding protein (FBP), the soluble form of the cellular membrane-bound folate receptor. We demonstrate that both choice of polymer and method of ligand conjugation affect the interactions between folic acid-polymer conjugates and serum FBP, resulting in changes in the folic acid-induced protein aggregation process. We have previously demonstrated that individual FBP molecules self-aggregate into nanoparticles at physiological concentrations. When poly(amidoamine) dendrimer-folic acid conjugates bound to FBP, the distribution of nanoparticles was preserved. However, the dendritic conjugates produced larger nanoparticles than those formed in the presence of physiologically normal human levels of folic acid, and the conjugation method affected particle size distribution. In contrast, poly(ethylene glycol)-folic acid conjugates demonstrated substantially reduced binding to FBP, did not cause folic acid-induced aggregation, and fully disrupted FBP self-aggregation. On the basis of these results, we discuss the potential implications for biodistribution, trafficking, and therapeutic efficacy of targeted nanoscale therapeutics, especially considering the widespread clinical use of poly(ethylene glycol) conjugates. We highlight the importance of considering specific serum protein interactions in the rational design of similar nanocarrier systems. Our results suggest that prebinding therapeutic nanocarriers to serum FBP may allow folate-specific metabolic pathways to be exploited for delivery while also affording benefits of utilizing an endogenous protein as a vector.

AB - Serum proteins play a critical role in the transport, uptake, and efficacy of targeted drug therapies, and here we investigate the interactions between folic acid-polymer conjugates and serum folate binding protein (FBP), the soluble form of the cellular membrane-bound folate receptor. We demonstrate that both choice of polymer and method of ligand conjugation affect the interactions between folic acid-polymer conjugates and serum FBP, resulting in changes in the folic acid-induced protein aggregation process. We have previously demonstrated that individual FBP molecules self-aggregate into nanoparticles at physiological concentrations. When poly(amidoamine) dendrimer-folic acid conjugates bound to FBP, the distribution of nanoparticles was preserved. However, the dendritic conjugates produced larger nanoparticles than those formed in the presence of physiologically normal human levels of folic acid, and the conjugation method affected particle size distribution. In contrast, poly(ethylene glycol)-folic acid conjugates demonstrated substantially reduced binding to FBP, did not cause folic acid-induced aggregation, and fully disrupted FBP self-aggregation. On the basis of these results, we discuss the potential implications for biodistribution, trafficking, and therapeutic efficacy of targeted nanoscale therapeutics, especially considering the widespread clinical use of poly(ethylene glycol) conjugates. We highlight the importance of considering specific serum protein interactions in the rational design of similar nanocarrier systems. Our results suggest that prebinding therapeutic nanocarriers to serum FBP may allow folate-specific metabolic pathways to be exploited for delivery while also affording benefits of utilizing an endogenous protein as a vector.

UR - http://www.scopus.com/inward/record.url?scp=85029670553&partnerID=8YFLogxK

U2 - 10.1021/acs.bioconjchem.7b00373

DO - 10.1021/acs.bioconjchem.7b00373

M3 - Article

VL - 28

SP - 2350

EP - 2360

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 9

ER -

Merzel RL, Frey C, Chen J, Garn R, Van Dongen M, Dougherty CA et al. Conjugation Dependent Interaction of Folic Acid with Folate Binding Protein. Bioconjugate Chemistry. 2017 Sep 20;28(9):2350-2360. https://doi.org/10.1021/acs.bioconjchem.7b00373